Biotinylated Human SOST/Sclerostin Protein
Catalog No: SOST-HB002
- Species
- Human
- Expression System
- HEK293
- Tag
- His, Avi
- Activity
- Activity verified
Product overview
Recombinant Biotinylated Human SOST/Sclerostin Protein is expressed in HEK293 cells with a His and Avi tag at the N-terminus. It contains amino acid residues Gln24-Tyr213 (UniProt accession: Q9BQB4-1).
Product Details
- Molecular Aliases
- sclerostin; SOST; VBCHsclerosteosis; CDD; DAND6; SOST1; VBCH
- Protein Length
- Gln24-Tyr213
- Expression System
- HEK293
- Theoretical Molecular Weight
- The protein has a predicted MW of 24.2 kDa. Due to glycosylation,the protein migrates to 28-40 kDa based on Bis-Tris PAGE result.
- Purity
- > 95% as determined by Bis-Tris PAGE
- Endotoxin
- Less than 1 EU per μg by the LAL method.
- Buffer / Formulation
- Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.
- State
- Lyophilized
- Storage Conditions
- -20 to -80°C for 12 months as supplied from date of receipt. -80°C for 3 months after reconstitution. Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.
- Reconstitution Advice
- Dissolve the lyophilized protein in distilled water. Please refer to the Certificate of Analysis for detailed instructions.
Data Display
Biotinylated Human SOST on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.
Immobilized Biotinylated Human SOST, His Tag at 5μg/ml (100μl/well) on the streptavidin precoated plate (5μg/ml). Dose response curve for Human LRP-6, mFc Tag with the EC50 of 8.7ng/ml determined by ELISA (QC Test).
Immobilized Anti-SOST Antibody at 1μg/ml (100μl/well) on the plate. Dose response curve for Biotinylated Human SOST, His Tag with the EC50 of 9.6ng/ml determined by ELISA.
Background
SOST, also known as sclerostin, is a member of the cerberus/DAN family, a group of secreted glycoproteins characterized by a cysteine-knot motif. SOST is negative regulator of bone growth that acts through inhibition of Wnt signaling and bone formation.
References
- Claire M N, Patton D, Hayes J S. Sclerostin Antibody Therapy for the Treatment of Osteoporosis: Clinical Prospects and Challenges[J]. Journal of Osteoporosis, 2016, 2016:1-22.
Have questions about this product?
Our technical team can help with product selection, application questions and order support.